Pharmacological induction of human fetal globin gene in hydroxyurea-resistant primary adult erythroid cells

Molecular and Cellular Biology

Volumn 35, Issue 14, 2015, Pages 2541-2553

  Chou, Yu Chi ^a   Chen, Ruei Lin ^a   Lai, Zheng Sheng ^a   Song, Jen Shin ^b   Chao, Yu Sheng ^b   Shen, Che Kun James ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; HEMOGLOBIN A; HEMOGLOBIN BETA CHAIN; HEMOGLOBIN F; HEMOGLOBIN GAMMA CHAIN; HISTONE H3; HISTONE H4; HYDROXYUREA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; ANTINEOPLASTIC AGENT; MOLECULAR LIBRARY;

ADULT; ANIMAL CELL; ARTICLE; BETA THALASSEMIA; CHROMATIN STRUCTURE; ENZYME ACTIVATION; ERYTHROID CELL; FLOW CYTOMETRY; GLOBIN GENE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANEMIA, SICKLE CELL; ANIMAL; BETA-THALASSEMIA; CELL CULTURE; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; K-562 CELL LINE; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; PRIMARY CELL CULTURE; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ADULT; ANEMIA, SICKLE CELL; ANIMALS; ANTINEOPLASTIC AGENTS; BETA-THALASSEMIA; BLOTTING, WESTERN; BUTYRIC ACID; CELL LINE, TUMOR; CELLS, CULTURED; DRUG RESISTANCE; ERYTHROID CELLS; FETAL HEMOGLOBIN; GAMMA-GLOBINS; HUMANS; HYDROXYUREA; K562 CELLS; MAP KINASE SIGNALING SYSTEM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PRIMARY CELL CULTURE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SMALL MOLECULE LIBRARIES; TRANSCRIPTIONAL ACTIVATION;

EID: 84932621889     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00035-15     Document Type: Article

References (66)

1. Weatherall DJ. 2001. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet 2:245-255. http://dx.doi.org/10.1038/35066048.
2. Patrinos GP, Grosveld FG. 2008. Pharmacogenomics and therapeutics of hemoglobinopathies. Hemoglobin 32:229-236. http://dx.doi.org/10.1080/03630260701680367.
3. Schechter AN. 2008. Hemoglobin research and the origins of molecular medicine. Blood 112:3927-3938. http://dx.doi.org/10.1182/blood-2008-04-078188.
4. Bauer DE, Kamran SC, Orkin SH. 2012. Reawakening fetal hemoglobin: prospects for new therapies for the beta-globin disorders. Blood 120: 2945-2953. http://dx.doi.org/10.1182/blood-2012-06-292078.
5. Higgs DR, Engel JD, Stamatoyannopoulos G. 2012. Thalassaemia. Lancet 379:373-383. http://dx.doi.org/10.1016/S0140-6736(11)60283-3.
6. Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S. 2010. Fetal globin gene inducers: novel agents and new potential. Ann N Y Acad Sci 1202:158-164. http://dx.doi.org/10.1111/j.1749-6632.2010.05593.x.
7. Natta CL, Niazi GA, Ford S, Bank A. 1974. Balanced globin chain synthesis in hereditary persistence of fetal hemoglobin. J Clin Invest 54: 433-438. http://dx.doi.org/10.1172/JCI107779.
8. Noguchi CT, Rodgers GP, Serjeant G, Schechter AN. 1988. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med 318:96-99. http://dx.doi.org/10.1056/NEJM198801143180207.
9. Ley TJ, Nienhuis AW. 1985. Induction of hemoglobin F synthesis in patients with beta thalassemia. Annu Rev Med 36:485-498. http://dx.doi.org/10.1146/annurev.me.36.020185.002413.
10. Humphries RK, Dover G, Young NS, Moore JG, Charache S, Ley T, Nienhuis AW. 1985. 5-Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin. J Clin Invest 75:547-557. http://dx.doi.org/10.1172/JCI111731.
11. Olivieri NF, Weatherall DJ. 1998. The therapeutic reactivation of fetal haemoglobin. Hum Mol Genet 7:1655-1658. http://dx.doi.org/10.1093/hmg/7.10.1655.
12. McCaffrey PG, Newsome DA, Fibach E, Yoshida M, Su MS. 1997. Induction of gamma-globin by histone deacetylase inhibitors. Blood 90: 2075-2083.
13. Witt O, Monkemeyer S, Ronndahl G, Erdlenbruch B, Reinhardt D, Kanbach K, Pekrun A. 2003. Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. Blood 101:2001-2007. http://dx.doi.org/10.1182/blood-2002-08-2617.
14. Constantoulakis P, Knitter G, Stamatoyannopoulos G. 1989. On the induction of fetal hemoglobin by butyrates: in vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-AzaC and AraC. Blood 74:1963-1971.
15. Fucharoen S, Inati A, Siritanaratku N, Thein SL, Wargin WC, Koussa S, Taher A, Chaneim N, Boosalis M, Berenson R, Perrine SP. 2013. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in beta-thalassaemia intermedia and HbE/beta-thalassaemia. Br J Haematol 161:587-593. http://dx.doi.org/10.1111/bjh.12304.
16. Grigg A. 2007. Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease. Intern Med J 37:190-192. http://dx.doi.org/10.1111/j.1445-5994.2006.01290.x.
17. Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE. 1999. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 94:1550-1554.
18. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ. 1997. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter study of hydroxyurea. Blood 89:1078-1088.
19. Atweh G, Fathallah H. 2010. Pharmacologic induction of fetal hemoglobin production. Hematol Oncol Clin North Am 24:1131-1144. http://dx.doi.org/10.1016/j.hoc.2010.08.001.
20. Sankaran VG, Menne TF, Xu J, Akie TE, Lettre G, Van Handel B, Mikkola HK, Hirschhorn JN, Cantor AB, Orkin SH. 2008. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 322:1839-1842. http://dx.doi.org/10.1126/science.1165409.
21. Zhou W, Clouston DR, Wang X, Cerruti L, Cunningham JM, Jane SM. 2000. Induction of human fetal globin gene expression by a novel erythroid factor, NF-E4. Mol Cell Biol 20:7662-7672. http://dx.doi.org/10.1128/MCB.20.20.7662-7672.2000.
22. Jiang J, Best S, Menzel S, Silver N, Lai MI, Surdulescu GL, Spector TD, Thein SL. 2006. cMYB is involved in the regulation of fetal hemoglobin production in adults. Blood 108:1077-1083. http://dx.doi.org/10.1182/blood-2006-01-008912.
23. Pace B, Qian X, Sangerman J, Oforiacquah S, Baliga B, Han J, Critz S. 2003. p38 MAP kinase activation mediates γ-globin gene induction in erythroid progenitors. Exp Hematol 31:1089-1096. http://dx.doi.org/10.1016/S0301-472X(03)00235-2.
24. Ramakrishnan V, Pace BS. 2011. Regulation of gamma-globin gene expression involves signaling through the p38 MAPK/CREB1 pathway. Blood Cells Mol Dis 47:12-22. http://dx.doi.org/10.1016/j.bcmd.2011.03.003.
25. Forrester WC, Novak U, Gelinas R, Groudine M. 1989. Molecular analysis of the human beta-globin locus activation region. Proc Natl Acad Sci U S A 86:5439-5443. http://dx.doi.org/10.1073/pnas.86.14.5439.
26. Bodine DM, Ley TJ. 1987. An enhancer element lies 3' to the human A gamma globin gene. EMBO J 6:2997-3004.
27. Singer D, Cooper M, Maniatis GM, Marks PA, Rifkind RA. 1974. Erythropoietic differentiation in colonies of cells transformed by Friend virus. Proc Natl Acad Sci U S A 71:2668-2670. http://dx.doi.org/10.1073/pnas.71.7.2668.
28. Andersson LC, Nilsson K, Gahmberg CG. 1979. K562-a human erythroleukemic cell line. Int J Cancer 23:143-147. http://dx.doi.org/10.1002/ijc.2910230202.
29. Yue QF, Xiong B, Chen WX, Liu XY. 2014. Comparative study of the efficacy of Wright-Giemsa stain and Liu's stain in the detection of Auer rods in acute promyelocytic leukemia. Acta Histochem 116:1113-1116. http://dx.doi.org/10.1016/j.acthis.2014.05.005.
30. Daftari P, Gavva NR, Shen CK. 1999. Distinction between AP1 and NF-E2 factor-binding at specific chromatin regions in mammalian cells. Oncogene 18:5482-5486. http://dx.doi.org/10.1038/sj.onc.1202916.
31. Vadolas J, Wardan H, Orford M, Voullaire L, Zaibak F, Williamson R, Ioannou PA. 2002. Development of sensitive fluorescent assays for embryonic and fetal hemoglobin inducers using the human beta-globin locus in erythropoietic cells. Blood 100:4209-4216. http://dx.doi.org/10.1182/blood-2001-12-0365.
32. Chan KS, Xu J, Wardan H, McColl B, Orkin S, Vadolas J. 2012. Generation of a genomic reporter assay system for analysis of gamma-and beta-globin gene regulation. FASEB J 26:1736-1744. http://dx.doi.org/10.1096/fj.11-199356.
33. Xu J, Sankaran VG, Ni M, Menne TF, Puram RV, Kim W, Orkin SH. 2010. Transcriptional silencing of gamma-globin by BCL11A involves long-range interactions and cooperation with SOX6. Genes Dev 24:783-798. http://dx.doi.org/10.1101/gad.1897310.
34. Orkin SH. 1992. GATA-binding transcription factors in hematopoietic cells. Blood 80:575-581.
35. Bulger M, Sawado T, Schubeler D, Groudine M. 2002. ChIPs of the beta-globin locus: unraveling gene regulation within an active domain. Curr Opin Genet Dev 12:170-177. http://dx.doi.org/10.1016/S0959-437X(02)00283-6.
36. Bieker JJ. 2005. Probing the onset and regulation of erythroid cell-specific gene expression. Mt Sinai J Med 72:333-338.
37. Raich N, Clegg CH, Grofti J, Romeo PH, Stamatoyannopoulos G. 1995. GATA1 and YY1 are developmental repressors of the human epsilonglobin gene. EMBO J 14:801-809.
38. Tanabe O, McPhee D, Kobayashi S, Shen Y, Brandt W, Jiang X, Campbell AD, Chen YT, Chang C, Yamamoto M, Tanimoto K, Engel JD. 2007. Embryonic and fetal beta-globin gene repression by the orphan nuclear receptors, TR2 and TR4 EMBO J 26:2295-2306. http://dx.doi.org/10.1038/sj.emboj.7601676.
39. Gallarda JL, Foley KP, Yang ZY, Engel JD. 1989. The beta-globin stage selector element factor is erythroid-specific promoter/enhancer binding protein NF-E4. Genes Dev 3:1845-1859. http://dx.doi.org/10.1101/gad.3.12a.1845.
40. Chen RL, Chou YC, Lan YJ, Huang TS, Shen CK. 2010. Developmental silencing of human zeta-globin gene expression is mediated by the transcriptional repressor RREB1. J Biol Chem 285:10189-10197. http://dx.doi.org/10.1074/jbc.M109.049130.
41. Xu J, Peng C, Sankaran VG, Shao Z, Esrick EB, Chong BG, Ippolito GC, Fujiwara Y, Ebert BL, Tucker PW, Orkin SH. 2011. Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science 334:993-996. http://dx.doi.org/10.1126/science.1211053.
42. Chen Z, Luo HY, Steinberg MH, Chui DH. 2009. BCL11A represses HBG transcription in K562 cells. Blood Cells Mol Dis 42:144-149. http://dx.doi.org/10.1016/j.bcmd.2008.12.003.
43. Weinberg RS, Ji X, Sutton M, Perrine S, Galperin Y, Li Q, Liebhaber SA, Stamatoyannopoulos G, Atweh GF. 2005. Butyrate increases the efficiency of translation of gamma-globin mRNA. Blood 105:1807-1809. http://dx.doi.org/10.1182/blood-2004-02-0454.
44. Yang YM, Pace B, Kitchens D, Ballas SK, Shah A, Baliga BS. 1997. BFU-E colony growth in response to hydroxyurea: correlation between in vitro and in vivo fetal hemoglobin induction. Am J Hematol 56:252-258. http://dx.doi.org/10.1002/(SICI)1096-8652(199712)56:4<252::AIDAJH10>l3.0.CO;2-B.
45. Skarpidi E, Vassilopoulos G, Li Q, Stamatoyannopoulos G. 2000. Novel in vitro assay for the detection of pharmacologic inducers of fetal hemoglobin. Blood 96:321-326.
46. Migliaccio G, Di Baldassarre A, Di Rico C, Di Noia A, Nakamoto B, Cao H, Skarpidi E, Migliaccio AR. 2005. Spontaneous switch from Agammato beta-globin promoter activity in a stable transfected dual reporter vector. Blood Cells Mol Dis 34:174-180. http://dx.doi.org/10.1016/j.bcmd.2004.11.005.
47. Nam TG, Lee J, Walker JR, Brinker A, Cho CY, Schultz PG. 2011. Identification and characterization of small-molecule inducers of fetal hemoglobin. ChemMedChem 6:777-780. http://dx.doi.org/10.1002/cmdc.201000505.
48. Pace BS, White GL, Dover GJ, Boosalis MS, Faller DV, Perrine SP. 2002. Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. Blood 100:4640-4648. http://dx.doi.org/10.1182/blood-2002-02-0353.
49. Constantoulakis P, Papayannopoulou T, Stamatoyannopoulos G. 1988. α-Amino-N-butyric acid stimulates fetal hemoglobin in the adult. Blood 72:1961-1967.
50. Liakopoulou E, Blau CA, Li Q, Josephson B, Wolf JA, Fournarakis B, Raisys V, Dover G, Papayannopoulou T, Stamatoyannopoulos G. 1995. Stimulation of fetal hemoglobin production by short chain fatty acids. Blood 86:3227-3235.
51. Inati A, Kahale M, Perrine SP, Chui DH, Taher AT, Koussa S, Abi Nasr T, Abbas HA, Ghalie RG. 2014. A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in beta-thalassaemia intermedia. Br J Haematol 164:456-458. http://dx.doi.org/10.1111/bjh.12635.
52. Kutlar A, Reid ME, Inati A, Taher AT, Abboud MR, El-Beshlawy A, Buchanan GR, Smith H, Ataga KI, Perrine SP, Ghalie RG. 2013. A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol 88:E255-E260. http://dx.doi.org/10.1002/ajh.23533.
53. Patthamalai P, Fuchareon S, Chaneiam N, Ghalie RG, Chui DH, Boosalis MS, Perrine SP. 2014. A phase 2 trial of HQK-1001 in HbE-beta thalassemia demonstrates HbF induction and reduced anemia. Blood 123: 1956-1957. http://dx.doi.org/10.1182/blood-2013-11-538470.
54. Reid ME, El Beshlawy A, Inati A, Kutlar A, Abboud MR, Haynes J, Jr, Ward R, Sharon B, Taher AT, Smith W, Manwani D, Ghalie RG. 2014. A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. AmJ Hematol 89:709-713. http://dx.doi.org/10.1002/ajh.23725.
55. Cokic VP, Smith RD, Beleslin-Cokic BB, Njoroge JM, Miller JL, Gladwin MT, Schechter AN. 2003. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest 111:231-239. http://dx.doi.org/10.1172/JCI16672.
56. Lou TF, Singh M, Mackie A, Li W, Pace BS. 2009. Hydroxyurea generates nitric oxide in human erythroid cells: mechanisms for gamma-globin gene activation. Exp Biol Med (Maywood, NJ) 234:1374-1382. http://dx.doi.org/10.3181/0811-RM-339.
57. Huwiler A, Pfeilschifter J. 1999. Nitric oxide stimulates the stressactivated protein kinase p38 in rat renal mesangial cells. J Exp Biol 202: 655-660.
58. Park JI, Choi HS, Jeong JS, Han JY, Kim IH. 2001. Involvement of p38 kinase in hydroxyurea-induced differentiation of K562 cells. Cell Growth Differ 12:481-486.
59. Witt O, Sand K, Pekrun A. 2000. Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. Blood 95:2391-2396.
60. Mabaera R, West RJ, Conine SJ, Macari ER, Boyd CD, Engman CA, Lowrey CH. 2008. A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them stronger. Exp Hematol 36:1057-1072. http://dx.doi.org/10.1016/j.exphem.2008.06.014.
61. Sankaran VG, Xu J, Ragoczy T, Ippolito GC, Walkley CR, Maika SD, Fujiwara Y, Ito M, Groudine M, Bender MA, Tucker PW, Orkin SH. 2009. Developmental and species-divergent globin switching are driven by BCL11A. Nature 460:1093-1097. http://dx.doi.org/10.1038/nature08243.
62. Zhou D, Liu K, Sun CW, Pawlik KM, Townes TM. 2010. KLF1 regulates BCL11A expression and gamma-to beta-globin gene switching. Nat Genet 42:742-744. http://dx.doi.org/10.1038/ng.637.
63. Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, Kinney TR. 1991. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 325:11-16.
64. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. 1994. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 330:1639-1644.
65. Powars DR, Weiss JN, Chan LS, Schroeder WA. 1984. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood 63:921-926.
66. Lebensburger JD, Pestina TI, Ware RE, Boyd KL, Persons DA. 2010. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica 95:1599-1603. http://dx.doi.org/10.3324/haematol.2010.023325.